298 studies found for:    Open Studies | "Carcinoma, Renal Cell"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Immunotherapy Study for Metastatic Renal Cell Cancer
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Clear-cell Renal Cancer;   Recurrent Renal Cell Carcinoma;   Refractory Renal Cell Carcinoma;   Metastatic Kidney Cancer
Intervention: Biological: HyperAcute®-Renal (HAR) Immunotherapy
2 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
3 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
4 Recruiting Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
Conditions: Carcinoma, Renal Cell;   Clear Cell Renal Cell Carcinoma
Intervention: Drug: axitinib
5 Recruiting A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Kidney Diseases;   Kidney Neoplasms;   Urogenital Neoplasms;   Urologic Diseases;   Urologic Neoplasms;   Neoplasms;   Neoplasms by Histologic Type;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Combination of varlilumab and sunitinib
6 Not yet recruiting Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
Conditions: Advanced Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: Sunitinib;   Drug: Isoquercetin;   Drug: Placebo
7 Recruiting Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
Condition: Carcinoma, Renal Cell
Interventions: Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Sorafenib;   Drug: Pazopanib;   Drug: Everolimus;   Drug: Axitinib
8 Unknown  Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Device: DCE-MRI and Quantitative Doppler Ultrasound
9 Recruiting Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib followed by everolimus
10 Recruiting Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Drug: MK-3475
11 Recruiting Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Pathology;   Treatment Outcome;   Hemoglobin A1c Protein, Human
Intervention:
12 Recruiting Myeloid Derived Suppressor Cells Clinical Assay in Finding and Monitoring Kidney Cancer
Conditions: Healthy Subject;   Metastatic Renal Cell Cancer;   Recurrent Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Procedure: Computed Tomography;   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Imaging
13 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Conditions: Carcinoma of the Collecting Ducts of Bellini;   Chromophobe Renal Cell Carcinoma;   Kidney Medullary Carcinoma;   Kidney Oncocytoma;   Papillary Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Intervention: Drug: Pazopanib Hydrochloride
14 Not yet recruiting Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
15 Recruiting Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Metastatic Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: Aldesleukin;   Procedure: Computed Tomography;   Drug: Entinostat;   Radiation: Fludeoxyglucose F-18;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Positron Emission Tomography
16 Unknown  Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
17 Recruiting Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer
Interventions: Biological: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
18 Recruiting Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
Conditions: Metastatic Renal Cell Cancer;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Radiation: Stereotactic Body Radiation Therapy
19 Recruiting Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
Interventions: Drug: Vandetanib;   Drug: Metformin
20 Recruiting Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Radiation: stereotactic body radiation therapy;   Drug: cyclophosphamide;   Biological: therapeutic autologous lymphocytes;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years